Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients

Article metrics

Abstract

In 2005, the National Institutes of Health (NIH) chronic graft-versus-host disease (cGVHD) consensus project provided diagnosis and staging criteria, based mostly on clinical experience and expert opinion. These criteria were revised in 2014, aiming to provide enhanced specificity and clarity. However, the impact of 2014 changes to the original NIH cGVHD severity scoring criteria has not been reported. In this study, 284 patients, prospectively enrolled on the National Cancer Institute's cross-sectional cGVHD natural history study, were scored using the 2005 NIH cGVHD criteria and then rescored according to the 2014 modifications. In comparing the two criteria, 2014 cGVHD global severity scoring resulted in a tendency toward being categorized as milder scores (75 vs. 72% of severe score per 2014, p = 0.0009), with a statistically significant shift in NIH liver and lung scores toward milder categories (p < 0.0001). 2005 and 2014 NIH global severity scores showed a significant association with reduced grip strength (p < 0.0001), reduced joint range of motion (p = 0.0003), and the subspecialist evaluation score (p < 0.0001). Poor survival prediction of the severe NIH lung score is also retained in the new criteria (p = 0.0012). These findings support the use of 2014 cGVHD scoring criteria in continuous efforts to develop better classification systems.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33. http://www.ncbi.nlm.nih.gov/pubmed/12720215

  2. 2.

    Martin PJ, Counts GW, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28:1011–6.

  3. 3.

    Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica. 2017;102:614–25.

  4. 4.

    Lee SJ, Kim HT, Ho VT, Cutler C, Alyea EP, Soiffer RJ, et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006;38:305–10. http://www.nature.com/doifinder/10.1038/sj.bmt.1705434

  5. 5.

    Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56. http://www.ncbi.nlm.nih.gov/pubmed/16338616

  6. 6.

    Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17. http://www.ncbi.nlm.nih.gov/pubmed/6996481

  7. 7.

    Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2015;21:389–401.e1. http://www.ncbi.nlm.nih.gov/pubmed/25529383

  8. 8.

    Baird K, Steinberg SM, Grkovic L, Pulanic D, Cowen EW, Mitchell SA, et al. National Institutes of Health Chronic Graft-versus-Host Disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. Biol Blood Marrow Transplant. 2013;19:632–9. http://linkinghub.elsevier.com/retrieve/pii/S1083879113000372

  9. 9.

    Moon JH, Sohn SK, Lambie A, Ellis L, Hamad N, Uhm J, et al. Validation of National Institutes of Health Global Scoring System for Chronic Graft-Versus-Host Disease (GVHD) According to Overall and GVHD-Specific Survival. Biol Blood Marrow Transplant. 2014;20:556–63. http://www.ncbi.nlm.nih.gov/pubmed/24447907

  10. 10.

    Merkel EC, Mitchell SA, Lee SJ. Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews. Biol Blood Marrow Transplant. 2016;22:752–8. http://www.ncbi.nlm.nih.gov/pubmed/26751003

  11. 11.

    Lee Sk, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8:444–52. http://www.ncbi.nlm.nih.gov/pubmed/12234170

  12. 12.

    McQuellon RP, Russell GB, Cella DF, Craven BL, Brady M, Bonomi A, et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant. 1997;19:357–68. http://www.ncbi.nlm.nih.gov/pubmed/9051246

  13. 13.

    Herzberg PY, Heussner P, Mumm FHA, Horak M, Hilgendorf I, von Harsdorf S, et al. Validation of the Human Activity Profile Questionnaire in patients after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16:1707–17. http://www.ncbi.nlm.nih.gov/pubmed/20541028

  14. 14.

    Pidala J, Chai X, Martin P, Inamoto Y, Cutler C, Palmer J, et al. Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium. Biol Blood Marrow Transplant. 2013;19:967–72. http://linkinghub.elsevier.com/retrieve/pii/S1083879113001407

  15. 15.

    American Academy of Orthopaedic Surgeons. Joint motion: method of measuring and recording. Chicago, IL: American Academy of Orthopaedic Surgeons; 1965. http://www.worldcat.org/title/joint-motion-method-of-measuring-and-recording/oclc/301640901

  16. 16.

    Mitchell SA, Leidy NK, Mooney KH, Dudley WN, Beck SL, LaStayo PC, et al. Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant. 2010;45:762–9. http://www.ncbi.nlm.nih.gov/pubmed/19784078

  17. 17.

    Bewick V, Cheek L, Ball J. Statistics review 10: further nonparametric methods. Crit Care. 2004;8:196–9. http://www.ncbi.nlm.nih.gov/pubmed/15153238

  18. 18.

    Agresti A. Categorical data analysis. In: Wiley series in probability and statistics. Hoboken, NJ: John Wiley & Sons, Inc.; 2002. http://doi.wiley.com/10.1002/0471249688

  19. 19.

    Hollander M, Wolfe DA. Solutions manual to accompany nonparametric statistical methods. Hoboken, NJ: Wiley; 1999. 162p.

  20. 20.

    Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–68. http://erj.ersjournals.com/content/26/5/948.long

  21. 21.

    Greinix HT, Loddenkemper C, Pavletic SZ, Holler E, Socié G, Lawitschka A, et al. Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant. 2011;17:167–75. http://www.ncbi.nlm.nih.gov/pubmed/20691801

  22. 22.

    Aki SZ, Inamoto Y, Carpenter PA, Storer BE, Sandmaier BM, Lee SJ, et al. Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity. Bone Marrow Transplant. 2016;51:1350–3. http://www.ncbi.nlm.nih.gov/pubmed/27214071

  23. 23.

    Ditz D, Rabanus R, Schulz C, Wolff D, Holler B, Holler E, et al. The lung function score and its components as predictors of overall survival and chronic graft-vs-host disease after allogeneic stem cell transplantation. Croat Med J. 2016;57:16–28. http://www.ncbi.nlm.nih.gov/pubmed/26935611

  24. 24.

    Walter EC, Orozco-Levi M, Ramirez-Sarmiento A, Vigorito A, Campregher PV, Martin PJ, et al. Lung function and long-term complications after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transplant. 2010;16:53–61. http://www.ncbi.nlm.nih.gov/pubmed/20053332

  25. 25.

    Lazaryan A, Arora M. Evolving concepts in prognostic scoring of chronic GvHD. Bone Marrow Transplant. 2017;52:1361–66. http://www.ncbi.nlm.nih.gov/pubmed/28346419

Download references

Author information

Correspondence to Ana Zelic Kerep.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kerep, A.Z., Broome, J., Pirsl, F. et al. Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients. Bone Marrow Transplant 54, 76–84 (2019) doi:10.1038/s41409-018-0224-3

Download citation

Further reading